Helicobacter pylori antibiotic resistance in Brazil: Clarithromycin is still a good option;Resistència do Helicobacter pylori aos antibióticos no Brasil: A claritromicina ainda é umu7a boa opção

Arquivos de Gastroenterologia

Volumn 48, Issue 4, 2011, Pages 261-264

  Eisig, Jaime Natan ^a   Silva, Fernando Marcuz ^a   Barbuti, Ricardo Correa ^a   Navarro Rodriguez, Tomás ^a   Moraes Filho, Joaquim Prado P ^a   Pedrazzoli Jr, José ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSIDADE SÃO FRANCISCO   (Brazil)

Author keywords

Amoxicillin; Clarithromycin; Drug resistance; Helicobacter pylori; Microbial

Indexed keywords

AMOXICILLIN; BISMUTH; CLARITHROMYCIN; FURAZOLIDONE; LEVOFLOXACIN; METRONIDAZOLE; TETRACYCLINE;

ADULT; AGAR DILUTION; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BRAZIL; CLINICAL ARTICLE; DYSPEPSIA; EPSILOMETER TEST; FEMALE; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STOMACH; STOMACH ANTRUM; STOMACH BIOPSY; STOMACH BODY; STOMACH FUNDUS; UPPER GASTROINTESTINAL TRACT; URBAN POPULATION;

EID: 83355173182     PISSN: 00042803     EISSN: 16784219     Source Type: Journal    
DOI: 10.1590/S0004-28032011000400008     Document Type: Article

References (27)

1. Andreasen JJ, Andersen LP. In vitro susceptibility of Campylobacter pyloridis to cimetidine, sucralfate, bismuth and sixteen antibiotics. Acta Pathol Microbiol Immunol Scand B. 1987;95:147-9.
2. Calafatti SA, Ortiz RA, Deguer M, Martinez M, Pedrazzoli J Jr. Effect of acid secretion blockade by omeprazole on the relative bioavailability of orally administered furazolidone in healthy volunteers. Br J Clin Pharmacol. 2001;52:205-9.
3. Cammarota G, Cianci R, Cannizzaro O, Cuoco L, Pirozzi G, Gasbarrini A, Armuzzi A, Zocco MA, Santarelli L, Arancio F, Gasbarrini G. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther. 2000;14:1339-43.
4. Chang WL, Sheu BS, Cheng HC, Yang YJ, Yang HB, Wu JJ. Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan. J Gastroenterol Hepatol. 2009;24:1230-5.
5. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007; 102:1808-25.
6. Coelho LG, Zaterka S. [Second Brazilian Consensus Conference on Helicobacter pylori infection]. Arq Gastroenterol. 2005;42:128-32.
7. Dore MP, Piana A, Carta M, Atzei A, Are BM, Mura I, Massarelli G, Maida A, Sepulveda AR, Graham DY, Realdi G. Amoxycillin resistance is one reason for failure of amoxycillin-omeprazole treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 1998;12:635-9.
8. Ecclissato C, Marchioretto MA, Mendonca S, Godoy AP, Guersoni RA, Deguer M, Piovesan H, Ferraz JG, Pedrazzoli J. Increased primary resistance to recommended antibiotics negatively affects Helicobacter pylori eradication. Helicobacter. 2002;7:53-9.
9. Eisig JN, Silva FM, Barbuti RC, Rodriguez TN, Malfertheiner P, Moraes Filho JP, Zaterka S. Efficacy of a 7-day course of furazolidone, levofloxacin, and lansoprazole after failed Helicobacter pylori eradication. BMC Gastroenterol. 2009;9:38.
10. Fedorak RAA, Flamm R, Osato M, Stamler D. Antimicrobial susceptibility of H. pylori in Canada to three key antibiotics: metronidazole, clarithromycin, and amoxicillin. Gastroenterology. 1997;112:A115.
11. Filipec Kanizaj T, Katicic M, Skurla B, Ticak M, Plecko V, Kalenic S. Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronidazole triple-therapy regimens. Helicobacter. 2009;14:29-35.
12. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, Lam SK, Xiao SD, Tan HJ, Wu CY, Jung HC, Hoang BH, Kachintorn U, Goh KL, Chiba T, Rani AA. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 2009;24:1587-600.
13. Gisbert JP. "Rescue" regimens after Helicobacter pylori treatment failure. World J Gastroenterol. 2008;14:5385-402.
14. Gisbert JP, Pajares JM. Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther. 2002;16:1047-57.
15. Godoy AP, Ribeiro ML, Benvengo YH, Vitiello L, Miranda Mde C, Mendonça S, Pedrazzoli J Jr. Analysis of antimicrobial susceptibility and virulence factors in Helicobacter pylori clinical isolates. BMC Gastroenterol. 2003;3:20.
16. González C, García A, Daroch F, Kawaguchi F, Solar H, Rivera N, Vega E. [In vitro antimicrobial susceptibility of Helicobacter pylori strains: isolation of strains resistant to clarithromycin]. Rev Med Chil. 2001;129:643-6.
17. Graham DY. Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin Gastroenterol Hepatol. 2009;7:145-8.
18. Katelaris PH. Helicobacter pylori: antibiotic resistance and treatment options. J Gastroenterol Hepatol. 2009;24:1155-7.
19. Kim JM, Kim JS, Kim N, Jung HC, Song IS. Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients. J Antimicrob Chemother. 2005;56:965-7.
20. Kwon DH, Kim JJ, Lee M, Yamaoka Y, Kato M, Osato MS, El-Zaatari FA, Graham DY. Isolation and characterization of tetracycline resistant clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother. 2000;44:3203-5.
21. Lambert JR, Hansky J, Davidson A, Pinkard K, Stockman K. Campylobacter like organisms (CLO) in vivo and in vitro susceptibility to antimicrobials and antiulcer therapy. Gastroenterology. 1985;88:A1462
22. Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol. 2010;105:65-73.
23. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81.
24. Mendonça S, Ecclissato C, Sartori MS, Godoy AP, Guerzoni RA, Degger M, Pedrazzoli J Jr. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil. Helicobacter. 2000;5:79-83.
25. O'Connor A, Gisbert J, O'Morain C. Treatment of Helicobacter pylori infection. Helicobacter. 2009;14:46-51.
26. Sanches B, Coelho L, Moretzsohn L, Vieira G Jr. Failure of Helicobacter pylori treatment after regimes containing clarithromycin: new practical therapeutic options. Helicobacter. 2008;13:572-6.
27. Silva FM, Eisig JN, Chehter EZ, Silva JJ, Laudanna AA. Omeprazole, furazolidone, and tetracycline: an eradication treatment for resistant H. pylori in Brazilian patients with peptic ulcer disease. Rev Hosp Clin Fac Med Sao Paulo. 2002;57:205-8.